ASH Annual Meeting & Exposition: Leukemia | Conference

Matthew S. Davids, MD, MMSc, Discusses Extended Use of Venetoclax in CLL
January 26, 2022

Matthew S. Davids, MD, MMSc, spoke about the benefit of venetoclax combinations in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lindsey Roeker, MD, Discusses Potential for BTK Inhibition Plus Umbralisib/Ublituximab in CLL
January 17, 2022

Lindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.

Matthew S. Davids, MD, MMSc, Discusses Rationale for the MAJIC Study of Venetoclax Plus Acalabrutinib in CLL
January 12, 2022

Matthew S. Davids, MD, MMSc, spoke about using venetoclax plus acalabrutinib in the phase 3 MAJIC study for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lindsey Roeker, MD, Discusses the Outcomes of Using Ibrutinib With Umbralisib/Ublituximab in CLL
January 09, 2022

Lindsey Roeker, MD, spoke about phase 2 trial results which demonstrated efficacy of the combination of umbralisib and ublituximab added to ibrutinib for patients with chronic lymphocytic leukemia.

Acalabrutinib With or Without Obinutuzumab Improved Survival for Previously Untreated CLL
January 09, 2022

The combination of acalabrutinib, with or without obinutuzumab, produced a strong survival benefit for patients with treatment-naïve chronic lymphocytic leukemia over treatment with ibrutinib or venetoclax plus obinutuzumab.

KO-539 Plus Targeted Therapies Yields Synergistic Activity for KMT2A-Rearranged and NPM1-Mutated AML Models
January 04, 2022

Preclinical evidence supports further research in combining a menin inhibitor plus targeted therapies, as this may result in superior efficacy for patients with KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.

Lindsey Roeker, MD, Discusses Rationale for Investigating an Ibrutinib-Containing Triplet in CLL
January 03, 2022

Lindsey Roeker, MD, spoke about using a combination that includes a Bruton tyrosine kinase inhibitor, PI3K inhibitor, and an anti-CD20 monoclonal antibody for patients with chronic lymphocytic leukemia.

Acalabrutinib Plus Venetoclax To Be Evaluated in Treatment-Naive CLL/SLL
December 27, 2021

A non inferiority design was presented at ASH 2021 for acalabrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia or small lymphocytic leukemia.

Jennifer A. Woyach, MD, Discusses Use of Ibrutinib in CLL at 2021 ASH
December 21, 2021

Jennifer A. Woyach, MD, spoke about why it’s important to use newer therapies instead of chemoimmunotherapy for patients with chronic lymphocytic leukemia.

Sustained Survival Benefit Seen With Oral Azacitidine as Maintenance Therapy for AML in First Remission
December 15, 2021

Maintenance oral azacitidine produced a sustained survival benefit over placebo for patients with acute myeloid leukemia in first remission.